Allgens(SH:688613) Shang Hai Zheng Quan Bao·2026-01-28 18:01Group 1 - The company forecasts an estimated operating revenue of approximately 223.51 million yuan for the year 2025, representing an increase of about 17.47 million yuan or 8.48% compared to the previous year [1] - The company expects to achieve a net profit attributable to the parent company of around 13.53 million yuan for 2025, which indicates a turnaround from a loss of 26.19 million yuan compared to the previous year [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses is projected to be approximately -514,700 yuan, reflecting an increase of about 2.79 million yuan compared to the previous year [1] Group 2 - In 2024, the company reported an operating revenue of 206.03 million yuan and a net loss attributable to the parent company of 12.66 million yuan [2] - The basic earnings per share for the year 2024 was -0.09 yuan [2] - The increase in revenue is attributed to the orthopedic artificial bone procurement, which has provided opportunities for clinical usage and market share expansion, alongside enhanced production capabilities and refined marketing strategies [2]